Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH in the U.S. market. Phosphodiesterase-5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most prescribed first-line treatments; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies feature highly in the PAH treatment algorithm, and combination therapy is common. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated PAH patients receive pharmacotherapy in the United States.
Questions answered
Markets covered: United States.
Key companies: United Therapeutics, Actelion, Pfizer, Bayer, Gilead.
Key drugs: Opsumit, Tyvaso, Tyvaso DPI, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, ambrisentan, bosentan, sildenafil, tadalafil, epoprostenol.
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.